Preservation Solution Preventing Acetamide Formation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current preservation solutions for cells and organs in the absence of a blood supply generate undesirable degradation products like acetic acid and ammonia, which can be toxic and damage tissues, and react to form acetamide, a skin irritant and hazardous substance, limiting their effectiveness and safety for extended preservation.

Innovation Solution

A preservation solution comprising water, saccharides, pH buffers, calcium transport blockers, salicylic acid or aspirin, and glutamic acid or glutamine, with careful formulation to minimize or eliminate acetic acid, ammonia, and acetamide, ensuring the solution is free from these toxic compounds, thereby reducing cellular damage and extending preservation viability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If aspirin and glutamine are used in preservation solution, then anti-inflammatory and energy-providing functions are achieved, but toxic degradation products (acetic acid, ammonia, acetamide) are generated

Engineering Contradiction:
Improvepreservation effectivenessVSAvoidtoxic degradation products
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent removes the problematic components (aspirin and glutamine) from the preservation solution formula, replacing them with alternative substances that do not generate toxic degradation products during storage

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the chemical parameters of the preservation solution by substituting aspirin with salicylic acid and glutamine with glutamic acid, thereby altering the degradation profile to eliminate toxic byproducts while maintaining preservation functionality

Inventive Principle:
Principle #35Parameter changes

2Duration of action of stationary object

If preservation time is extended, then more organs can be preserved, but degradation products accumulate and increase toxicity

Engineering Contradiction:
Improvepreservation durationVSAvoidaccumulated degradation products
Core Design Contradiction:
Duration of action of stationary objectVSObject-generated harmful factors

Solution Approach 1:

The patent prevents the formation of toxic degradation products before they can accumulate by using chemically stable alternatives (salicylic acid and glutamic acid) that do not undergo harmful degradation reactions during the extended preservation period

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent converts the potential harm of long-term storage (degradation product accumulation) into a benefit by selecting components whose degradation products are non-toxic or easily metabolizable, thereby enabling extended preservation without toxicity concerns

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Stability of the object's composition

If acetamide forms from acetic acid and ammonia reaction, then degradation is complete, but skin irritation and liver damage risks increase

Engineering Contradiction:
Improvechemical stabilityVSAvoidskin irritation and liver damage
Core Design Contradiction:
Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and removes the precursors (acetic acid and ammonia) by eliminating their parent compounds (aspirin and glutamine) from the formula, thereby preventing the formation of acetamide and associated harmful effects

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces intermediate substances (salicylic acid and glutamic acid) that serve as safe alternatives, preventing the formation of harmful end products while maintaining the necessary physiological functions during preservation

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentEP3651576B1Preservation solutions
Publication Date: 2023.10.18 ORGAN PRESERVATION SOLUTIONS LTD
  • EP3651576B1 patent drawingFigure 1
  • EP3651576B1 patent drawingFigure 2
  • EP3651576B1 patent drawingFigure 3

AI summary

There is described a preservation solution for the preservation of cells, tissues and/or organs, said solution comprising: (i) water for injection; (ii) at least one saccharide; (iii) at least one component with pH buffer properties; (iv) optionally at least one component with calcium transport blocking properties or an anti-calcium action activity; (v) salicylic acid, in free form or in salt form, or aspirin; and (vi) glutamic acid, in free form or in salt form, or glutamine; provided that acetamide is absent and/or if aspirin is present glutamine is absent and if glutamine is present aspirin is absent.